To demonstrate that magnetic resonance (MR) imagingguided high-intensity focused ultrasound (HIFU) is a safe, effective, and durable treatment option for the management of osteoid osteoma in children and young adults.
This study was conducted as a spontaneous project without any direct funding. It can be considered self-funded through the Italian National Health System. Alessandro Napoli, as corresponding author, had full access to all of the data in the study and had final responsibility for the decision to submit this work for publication. q RSNA, 2017 Purpose:
To demonstrate that magnetic resonance (MR) imagingguided high-intensity focused ultrasound (HIFU) is a safe, effective, and durable treatment option for the management of osteoid osteoma in children and young adults.
Materials and Methods:
This prospective study was institutional review board approved and is registered with clinicaltrials.gov (identification number NCT02302651). Written informed consent was obtained from patients or their parents. Patients who had both clinical and radiologic findings that were diagnostic for nonvertebral osteoid osteoma and no contraindications to MR imaging-guided HIFU were enrolled between June 2010 and June 2013. The feasibility, safety, and clinical effectiveness of MR imaging-guided HIFU were considered primary outcomes; tumor control at imaging was considered a secondary outcome. Analyses were conducted on a per-protocol basis.
Results:
Forty-five of the 50 recruited patients underwent MR imaging-guided HIFU. All patients were discharged without treatment-related complications. The median visual analog scale (VAS) pain score (scale, 0-10) decreased from 8 before treatment to 0 at 1-week and 1-, 6-, 12-, 24-, and 36-month follow-up. Similarly, median VAS scores for the degree to which pain interfered with sleep and physical and daily activities decreased to 0 within the 1st month after treatment and remained stable at subsequent follow-up. Overall, 39 (87%) of the 45 patients achieved and maintained a VAS score of 0 during the 3-year observation period. Quality of life, as assessed by using Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improved, with the median FACT-BP score of 28 (points) before treatment increasing to a median score of 55 at 1-week follow-up and 60 at 6-month and subsequent follow-ups. At (final) 36-month follow-up, MR imaging depicted an absence of residual nidus vascularity in 32 (76%) of the 42 patients who were treated with MR imaging-guided HIFU only.
Conclusion:
The durable clinical efficacy and safety of MR imagingguided HIFU were demonstrated. These features are evidence of the potential of MR imaging-guided HIFU to be part of a routine strategy for the treatment of osteoid osteoma. 
Materials and Methods

Study Design and Patient Enrollment
We performed a prospective two-center developmental trial, as defined in the IDEAL (Idea, Development, Exploration, Assessment, and Long-term) guidelines for assessing innovation in surgery (20) . In addition, we followed the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting data (21, 22) . Our study was approved by the institutional review board and independently audited by hospital research and development officials. All patients older than 18 years provided written informed consent for study participation, and the parents of those younger than 18 years provided written consent. This trial is registered with clinicaltrials.gov (identification number NCT02302651). Patients could participate in the study if they received a diagnosis of with a failure rate of up to 15%, and procedure-related side effects include fracture (5%-20% of cases), osteomyelitis (30%-70% of cases), and functional limitation (5%-10% of cases). In addition, they involve required hospitalization and a prolonged period of limited activity (1) .
Minimally invasive percutaneous treatments with imaging guidance represent a feasible alternative to surgery; options include trephine excision, cryoablation, radiofrequency ablation (RFA), and laser thermocoagulation (6) (7) (8) (9) . These percutaneous methods are less invasive than surgery, require minimal postinterventional observation, can be used to treat disease in high-risk locations such as intra-articular and spinal areas, and cost less (10) (11) (12) . In a systematic review (13), pooled mean clinical success rates of 84%-95% were reported. The reported mean incomplete treatment rate was 2%, with recurrent pain in 4.9% of cases; moreover, complications were encountered in 2.1% of cases.
Magnetic resonance (MR) imaging-guided high-intensity focused ultrasound (HIFU) is a completely noninvasive modality (14, 15) with which the therapeutic energy can be focused transcutaneously, facilitating thermal ablation of the periosteal nerves and penetrating the medullary bone. This process leads to coagulation of the osteoid osteoma nidus, with promising results in terms of safety and clinical success (16) (17) (18) (19) . In this study, our purpose was to demonstrate that totally noninvasive focal nidus ablation performed https://doi.org/10.1148/radiol.2017162680
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Advances in Knowledge
n Treatment of nonspinal osteoid osteoma with noninvasive MR imaging-guided high-intensity focused ultrasound (HIFU) seems to be safe, as no treatmentrelated side effects were observed in the 45 patients in this study who underwent the procedure.
n Compared with the more invasive CT-guided radiofrequency ablation, the reference standard, MR-guided HIFU has similar clinical efficacy: 42 patients had a significant improvement in pain score after HIFU treatment only and required no further treatment and 39 patients achieved a general visual analogue scale score of 0, consistent with complete clinical response.
n Data in this study are evidence of the long-term efficacy of MRguided HIFU in terms of pain relief and improved quality of life; results of Wilcoxon signed rank testing to compare baseline with follow-up median values indicate that the beneficial effects of using this technique persisted and increased with time.
Implications for Patient Care
n MR-guided HIFU has durable clinical efficacy in the management of nonspinal osteoid osteoma, improving the physical capabilities and quality of life of individuals with this disease, which mainly occurs in the pediatric population.
n The totally noninvasive nature of MR imaging-guided HIFU offers a safety profile that compares favorably with that of current strategies.
T o date, the most appropriate therapy for patients with osteoid osteoma remains controversialmainly because of local medical competencies and patient-related factors (1) . Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) is easier, less expensive, and better tolerated in the short term. However, prolonged use of NSAIDs has substantial limitations, and a more pragmatic approach has been advocated to relieve pain and improve quality of life (2, 3) .
Surgical treatment of osteoid osteoma involves the use of an open approach for which en bloc resection of the osteoma nidus is required to achieve symptom relief (4, 5) . This technique has the disadvantages of large surgical exposure and excision of the affected bone, with bone grafting or internal fixation often required. Surgical approaches are associated MUSCULOSKELETAL IMAGING: MR Imaging-guided High-Intensity Focused Ultrasound for Osteoid Osteoma Napoli et al and an imaging-based diagnosis of osteoid osteoma according to previously established criteria (23), without lesion biopsy results, as in previously published studies (16,17) ( Fig 1) . We excluded patients with general contraindications to MR imaging, anesthesia, and/ or MR imaging-guided HIFU. Osteoma lesions were considered to be technically nonaccessible when the transcutaneous ultrasound beam path from the transducer to the osteoid osteoma lesion could cross energy-deflecting or energy-absorbing anatomic structures such as bowel or nontargeted bone. The initial results after 6 months for six patients in this series who were treated at a single site are reported in a previously published article (17) that is focused on the development of MR imaging-guided HIFU for noninvasive treatment of osteoid osteoma and provides preliminary safety and feasibility data. In this article, we report the long-term symptomatic nonvertebral osteoid osteoma. Patient enrollment started in June 2010 and ended in June 2013.
Because the primary objective of the study was to determine the clinical efficacy of MR imaging-guided HIFU ablation of osteoid osteoma, the sample size was powered by assuming an estimated clinical success rate of 90% at 36 months; this success rate was based on prior experience with MR imaging-guided HIFU treatment of osteoid osteoma (16) and the reported success rate for computed tomography (CT)-guided RFA (13) . Therefore, with an a level of .05 and a power of 90% (1 2 b), the sample size required was at least 39 patients. We adjusted the sample size to allow for an estimated dropout rate of 10% and therefore aimed to recruit a total of 44 patients with a clinical and imaging-based diagnosis of osteoid osteoma.
We included patients aged 4-45 years who had typical clinical features outcomes after performing MR imagingguided HIFU in a larger population of patients who were treated at two sites.
Preprocedural Evaluation
Overall pain intensity before treatment was assessed by using visual analog scale (VAS) scores on a scale of 0-10. Similar VAS scores were recorded to assess the degree to which pain interfered with sleep and physical activity (sports related and general daily)with and without NSAID use (according to individual pain/medication diary entries), as previously described (16) . Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores, in a 0-60-point scoring system, were used to measure quality of life (23, 24) ; the higher the score (ie, number of points), the better the quality of life.
Imaging evaluation involved the review of diagnostic nonenhanced CT scans and dynamic contrast materialenhanced MR images that were available before the HIFU ablation procedure. Two musculoskeletal radiologists (A.N., A.B.), each with at least 5 years of experience, evaluated a composite framework of findings in all patients, including cortical thickening adjacent to the nidus, bone edema, nidus enhancement after contrast agent injection (25, 26) , and periosteal and soft-tissue edema.
Treatment and Follow-up CT examinations and MR imaging examinations performed with 3.0-T (Discovery MR750; GE Medical Systems, Milwaukee, Wis) and 1.5-T (Discovery MR450; GE Medical Systems) units were repeated during the procedureplanning phase to locate the osteoid osteoma nidus and determine the optimal approach for treatment.
All MR imaging-guided HIFU procedures were performed by using a Conformité Européenne-approved system (ExAblate MRgFUS System; InSightec, Tirat-Carmel, Israel) and following previously established criteria for clinical practice (16, 17) . The number of sonications and degree of energy deposition for each treatment were recorded.
After HIFU treatment, the patients were monitored for 6 hours; during this MUSCULOSKELETAL IMAGING: MR Imaging-guided High-Intensity Focused Ultrasound for Osteoid Osteoma Napoli et al with these outcomes were scheduled for CT-guided RFA of the osteoid osteoma, unless they asked to undergo a second MR imaging-guided HIFU treatment, in which case the repeated procedure had to be technically feasible and the patient had to undergo a multidisciplinary evaluation. At the same time, quality of life was assessed by using standardized FACT-BP questionnaires. In this study, we compared the baseline scores with the follow-up results obtained at different time intervals (as previously described)-for up to 36 months. Tumor control at imaging was considered a secondary outcome. Specifically, the presence or absence of bone edema adjacent to the nidus, periosteal reactions and/or soft-tissue edema, and residual nidus vascularity were assessed at 36-month follow-up.
Statistical Analysis
Statistical analyses were performed by using nonparametric tests because normality was rejected with the Kologorov-Smirnov Z test. Validated questionnaire results were analyzed by using standard methods. Missing values for patient-reported outcome variables (between 2% and 10% missing values for individual questions) were imputed by using a fully conditional specification method and logistic regression model. The imputation was based on the observation of values missing completely at random. We classified the variables for which missing values were to be imputed as categorical. Therefore, logistic regression was used, with available values for the same variables at different time points on either side of the imputed value as predictors. Imputed values were rounded up to the next integer value. Maximal and minimal values were set according to extremes of questionnaire item scales. Categorical outcomes were reported as point estimates with binomial 95% confidence intervals (CIs) to demonstrate the level of precision. The Wilcoxon signed rank test was used to assess the differences between continuous variables that were not normally distributed (ie, VAS and FACT-BP questionnaire scores), as measured at baseline and follow-up visits. Changes over time were reported by using box-and-whisker plots. period, they were examined for possible skin burns and received analgesic medication if necessary. Those patients in whom general anesthesia was induced were hospitalized for 24 hours; the remaining patients were treated as outpatients. Follow-up consisted of clinical visits at 1, 6, 12, 24, and 36 months to report adverse events and complete VAS and FACT-BP questionnaires. Dynamic contrast-enhanced MR imaging of the treated areas was repeated in all patients at 12, 24, and 36 months. The entire study period, including enrollment and follow-up, was between June 2010 and July 2016.
Assessment of Treatment Outcomes
The feasibility, patient safety, and clinical outcomes associated with MR imaging-guided HIFU were considered primary outcomes. Feasibility was assessed by comparing the number of patients included in the study with the number of patients removed from the study owing to technical reasons (ie, lesions in nonaccessible regions, contraindications to HIFU procedure). Patient safety was reported in terms of rates and descriptions of postprocedural adverse eventsboth immediate (6-24 hours) and long term (1-36 months [27] )-with particular attention directed to lesions in critical locations such as in close proximity (5 mm) to the growth plate or articular cartilage. The posttreatment imaging examinations in particular were aimed at monitoring any macroscopic damage to the chondral surface, subchondral bone, and/or physeal cartilage.
Clinical effectiveness was reported in terms of pain palliation, as measured in scores recorded in the VAS questionnaire: A pain score of 0 a month after treatment with a stable status at follow-up was considered to indicate a complete response to treatment; otherwise, the clinical response was considered to be partial. Recurrence was reported if the patient's VAS score at follow-up was the same or greater than that before the HIFU treatment. Partial responses accompanied by high residual pain (VAS score  5) and recurrences were considered to indicate the technical failure of MR imaging-guided HIFU. Patients Subgroup analyses were deemed to be inappropriate for statistical analyses of significance in such comparisons because of the small numbers in each subgroup. P values of .05 or less were deemed to indicate a significant difference. All statistical tests were performed by using SPSS, version 17.0, software (IBM, Armonk, NY)).
Role of the Funding Source
Our study was conducted without direct external funding: Patient treatment, anesthesia, and hospitalization were funded by the Italian National Health System, which had no role in the design of the study; collection, analysis, or interpretation of data; or writing of the report. Three authors (A.N., M.A., L.S.) had access to the raw data. The corresponding author (A.N.) had full access to all of the data and final responsibility for the decision to submit this work for publication.
Results
Patient Enrollment
Fifty patients had typical clinical and radiologic findings of osteoid osteoma and were recruited between June 12, 2010, and June 30, 2013. None of them presented with contraindications to MR imaging. However, five patients had contraindications to the MR imaging-guided HIFU procedure and were treated with RFA: four with osteoid osteoma in a location inaccessible for MR imaging-guided HIFU treatment (frontal sinus in two patients, vertebral body in one patient, talar dome in one patient) and one with contraindications to anesthesia. Therefore, MR imaging-guided HIFU treatment was feasible in 45 (90%) of the 50 patients. These 45 patients had a mean age of 18 years (interquartile range [IQR], 16-25 years); 38 of them were male (mean age, 18 years; IQR, 16.0-24.5 years) and seven were female (mean age, 20 years; IQR, 14-27 years). The baseline characteristics of the study population are presented in Table 1 . The technical and procedural features associated with HIFU treatment are presented in Table 2 .
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Pain Evaluation after Treatment
All treated patients were discharged within 12-24 hours after the procedure, and none of them had complications related to the HIFU treatment or anesthesia. No long-term complications related to treatment were reported. In particular, no perilesional soft-tissue injury of the ligaments, cartilage, or menisci occurred with the treatment of areas next to joints; no growth impairment was recorded for young patients with treated lesions in proximity to the growth plate; and no skin burns occurred.
The overall VAS score after treatment indicated a significant reduction in pain severity (P , .001); the beneficial effect was continuous and increased with time ( Fig 2) . Sleep interference without NSAID intake (P , .001), overall physical activity capability without NSAID intake (P , .001), and sports and general daily activity capability (P , .001) had a similar trend (Fig 3) . Table 2 Procedural Factors Related to HIFU Treatment (Fig 4) . Overall, 42 patients (93%; 95% CI: 86%, 100%) had a significant (P , .05) improvement in pain score (VAS score range, 0-1) after treatment with MR imaging-guided HIFU only and did not require further clinical management. Specifically, 39 patients (87%, 95% CI: 77%, 97%) achieved a general VAS score of 0 within the 36-month follow-up period, consistent with a complete clinical response. In addition, sleep function the other three were treated with CTguided RFA, per the treatment protocol. Complete clinical success was achieved after the second line of intervention in all of these patients. The remaining five patients with a partial treatment response had a median VAS score of 2 (minimum, 1; maximum, 3) at 1-month follow-up. In two of these patients, the VAS score spontaneously decreased to 0 during subsequent clinical assessments, and in the remaining three, it stabilized to 1 and they required no further
The treatment response was complete (VAS score, 0) at 1-month follow-up in 36 of the 45 patients (80%; 95% CI: 68%, 92%), and no further treatment was requested during subsequent clinical assessments. In the remaining nine patients, the response was partial (mean VAS score, 3; IQR, 2-5), and four of them required further treatment because of discomfort related to residual pain. One of these four patients expressly asked to undergo another MR imaging-guided HIFU procedure, while MUSCULOSKELETAL IMAGING: MR Imaging-guided High-Intensity Focused Ultrasound for Osteoid Osteoma Napoli et al
The beneficial effect was stable and increased with time (P , .001) ( Fig 5) .
Imaging Evaluation after Treatment
At (final) 36-month MR imaging, all 42 patients who had been treated with only MR imaging-guided HIFU therapy had reduced bone edema and normalized periosteal and soft-tissue findings adjacent to the nidus. A complete absence of imaging-based evidence of residual nidus vascularity was documented in 32 of 42 patients (76%; 95% CI: 63%, 89%) who had a clinically significant response. On the other hand, three of the 10 patients with MR imaging findings of residual vascularity within the nidus at follow-up had clinically important residual pain and thus required a second-line intervention (Figs 6, 7) . The imaging outcomes are summarized in Table 4 .
Discussion
The outcomes of our study highlight the feasibility, safety, and long-term efficacy of MR imaging-guided HIFU treatment for osteoid osteoma. With respect to previous reports, our study results demonstrate the durable (at least 3-year) clinical benefit of this procedure in terms of not only pain relief but also pain's interference with sleep and activities, and overall quality of life. Overall, 45 of 50 patients with a clinical and radiologic diagnosis of osteoid osteoma fulfilled the established criteria and could undergo MR imaging-guided HIFU. The feasibility rate was high (90%) and comparable to reported feasibility rates for RFA (12, (28) (29) (30) (31) . The main reason for study dropouts was a vertebral or non-deviceaccessible location of the lesion. As far as potential procedure-related complications, investigators in previous studies (17) have speculated that MR imaging-guided HIFU might result in premature degenerative cartilage changes in patients with periarticular lesions. However, we observed no such alterations during our 3-year experience with clinical and imaging follow-up. Moreover, treating lesions that were adjacent to or within the growth plate resulted in a clinical benefit without during the baseline (time of intervention) to 1-week follow-up period, as indicated by FACT-BP scores, with the median FACT-BP score (number of points) increasing from 28 to 55 (P , .001). The FACT-BP questionnairebased outcomes during subsequent clinical assessments indicated further significant improvements in quality of life during the 1-week to 1-month follow-up period and the period from 1-month follow-up to subsequent assessments. was completely restored in 39 patients, and general physical limitations were resolved in 41 patients. Sports activity capability and daily physical activity capability returned to normal for 40 patients. After the HIFU procedure, all patients stopped taking NSAIDs ( Table 3 ).
Evaluation of Quality of Life after Treatment
All patients had a significant improvement in health-related quality of life [13] ). In our study population, MR imaging-guided HIFU resulted in a significant and persistent decrease in VAS scores, a significant and persistent increase in FACT-BP scores, and termination of NSAID use in all patients. One of the concerns regarding the use of focal strategies for the treatment of benign neoplasms such as osteoid osteomas is the consistent use of outcome measures for a sufficient period to assess regression of benefits or symptomatic relapse. A criticism of this emerging technology is that the structural preservation of the nidus during MR imaging-guided HIFU treatment, as compared with needlebased interventions such as CT-guided RFA, will lead to a greater symptom recurrence rate. This concern was the rationale for our long-term observation of outcomes after the HIFU treatment.
Our study results indicated that the beneficial effects of MR imaging-guided HIFU in terms of pain and quality of life for patients with osteoid osteoma are persistent and increase with timefrom the first to subsequent clinical follow-up visits.
At 36 months, 87% (n = 39) of 45 patients had achieved a complete clinical response (VAS score, 0) and 93% (n = 42) had a significant clinical improvement (VAS score, 0-1) compared with their baseline status. These results are comparable to those previously described with CT-guided RFA (13, 30, 31) and should be considered highly promising, providing evidence of a new clinical application for a recently introduced technology. In fact, the learning curve invariably affects initial results, especially in pediatric and young adult patients who undergo treatment of sensitive anatomic regions such as those near joints MUSCULOSKELETAL IMAGING: MR Imaging-guided High-Intensity Focused Ultrasound for Osteoid Osteoma Napoli et al further. Since the majority of patients with residual lesions at MR imaging had no symptoms and owing to the benign nature of osteoid osteomas, the imaging end point does not appear to be an appropriate metric for therapeutic success. We argue that symptom control and improved quality of life should remain the fundamental targeted outcomes of treatment.
Although the results of our current developmental study were not directly compared with the results of previous studies of focal therapy, they support the theory that tissue preservation leads to functional restoration. In terms of technical characteristics, MR imagingguided HIFU facilitates focal energy deposition that is sufficient to induce nidus ablation without damage to surrounding tissues. These features are of great benefit, especially in the pediatric population.
There were several limitations to our study. First, the number of participants included was small. Second, core-needle biopsy was not performed unsatisfactory outcomes-unlike with surgical and RFA procedures. Further studies are required to confirm this hypothesis because our protocol was designed such that primarily CT-guided RFA was offered in cases of failed MR imaging-guided HIFU.
The clinical results of MR imagingguided HIFU seem to be independent of the presence of residual nidus vascularity evaluated at MR imaging follow-up; nonetheless, the relationship between tissue restoration and MR imaging signs of edema should be investigated or growth plates. On the basis of the outcomes presented herein, the target of further and larger studies should be at least 90% complete clinical efficacy (VAS score, 0).
Partial clinical responses might be related to the nidus location and/ or partial ablation. In our study, at 1 month only four treated patients had residual symptoms that warranted a second line of treatment. In such cases, noninvasiveness is one of the strengths of MR imaging-guided HIFU, making repeat treatment feasible in cases of before the HIFU treatment; rather, the diagnosis was based only on consensus determinations made after clinical and imaging evaluations. However, biopsy is not mandatory to render a diagnosis of osteoid osteoma when the symptoms and imaging findings are considered typical. In addition, biopsy results are often inconclusive (32) (33) (34) . Third, as a safety measure, we excluded spinal lesions from our study owing to the risk of ablating near the spinal cord and nerve roots. However, osteoid osteoma is most frequently localized to nonvertebral skeletal segments. This work fulfilled the 2a stage component of the IDEAL guidelines for evaluating novel surgical strategies (20) ; the logical subsequent step should be a randomized trial to compare MR imaging-guided HIFU with CT-guided RFA (the standard of care) in terms of clinical efficacy and adverse events (stage 3). Alternatively, a multiple-nation registry of MR imaging-guided HIFU treatment for nonvertebral osteoid osteoma might be a feasible option for gathering sufficient data that could be used as a base for comparisons with CTguided RFA (35) . The Focused Ultrasound Foundation is providing funding support for the creation of an MR imaging-guided HIFU osteoid osteoma treatment registry. Concurrent development of a percutaneous osteoid osteoma treatment registry organized by the Society of Pediatric Interventional Radiology will enable direct comparisons of HIFU with traditional percutaneous treatment methods.
In conclusion, MR imaging-guided HIFU has potential as an effective technology for the noninvasive treatment of nonspinal osteoid osteoma in children and young adults. Our study results support the utility of MR imagingguided HIFU in reducing pain-related interference with sleep and activities and improving quality of life. The absence of adverse events and durable clinical efficacy associated with MR imaging-guided HIFU indicate its potential to be part of a routine strategy for treatment of osteoid osteoma in children and young adults.
